Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Glycated hemoglobin Stories

2013-09-04 08:31:37

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that NewMet(TM), the delayed-release formulation of generic metformin for the treatment of patients with Type 2 diabetes, met its primary study endpoint with statistically significant reductions in fasting plasma glucose at four weeks of treatment compared to placebo. The results from the randomized, 240-patient, multicenter U.S. Phase 2b trial confirm previous studies that showed NewMet reduced...

2013-09-04 08:18:58

A study based on a nationally representative sample of adults in China in 2010 indicates that nearly 12 percent of Chinese adults had diabetes and the prevalence of prediabetes was about 50 percent, according to a study in the September 4 issue of JAMA. "Noncommunicable chronic diseases have become the leading causes of mortality and disease burden worldwide. It was estimated that 34.5 million deaths globally were due to noncommunicable diseases in 2010, which reflected a significant...

2013-08-19 13:18:30

The longest and largest study of the effectiveness of insulin pumps to treat type 1 diabetes in children has shown that the pumps are more effective at controlling blood sugar than insulin injections and cause fewer complications. The research is published in Diabetologia, the journal of the European Association for the Study of Diabetes, and is by Associate Professor Elizabeth Davis, Princess Margaret Hospital for Children, Perth, WA, Australia and colleagues. The increasing use of...

2013-08-08 09:26:53

University of Washington-Group Health study in New England Journal of Medicine A joint Group Health–University of Washington (UW) study in the New England Journal of Medicine has found that higher blood sugar levels are associated with higher dementia risk, even among people who do not have diabetes. Blood sugar levels averaged over a five-year period were associated with rising risks for developing dementia, in this report about more than 2,000 Group Health patients...

2013-07-30 12:28:20

OAKLAND, Calif., July 30, 2013 /PRNewswire/ -- Patients with diabetes who take certain types of medications to lower their blood sugar sometimes experience severe low blood-sugar levels, whether or not their diabetes is poorly or well controlled, according to a new study by Kaiser Permanente and Yale University School of Medicine. The finding, published in the current online issue of Diabetes Care, challenges the conventional wisdom that hypoglycemia is primarily a problem among...

2013-07-18 23:22:39

Healthy Directions, a leading source of natural health advice and doctor-formulated nutritional products, announces the launch of Berberine+ GlucoDefense™, a proprietary blend of three ingredients that support healthy blood sugar levels. Potomac, MD (PRWEB) July 18, 2013 Healthy Directions, LLC, today announced the launch of Berberine+ GlucoDefense™, a unique blood sugar supplement formulated by Julian Whitaker, MD, that safely and naturally supports normal blood glucose and...

2013-07-15 23:00:21

New book details how Johnson’s wife coped with Type II diabetes in, ‘How My Wife Saved Her Life.’ COMPTON, MD. (PRWEB) July 16, 2013 Nearly 26 million Americans suffer from diabetes, says the American Diabetes Association. Sharon Johnson, wife of author Paige Johnson, was shocked and horrified when she joined the ranks of the 26 million other Americans. Diagnosed with Type 2 Diabetes, Sharon knew she had to make some serious changes to her life if she was going to survive....

2013-07-10 08:27:22

Randomized, Controlled Phase III Clinical Data Demonstrate Generex Oral-lyn's Effectiveness and Non-Inferiority When Compared to Injected Human Insulin WORCESTER, Mass. and TORONTO, July 10, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced the results of a Phase 3 clinical trial, conducted by its Indian licensee, Shreya Life Sciences Pvt. Ltd. (www.shreya.co.in), of Generex Oral-lyn(TM), the Company's proprietary buccal insulin...

2013-06-23 20:20:04

Phase 3 Results for INVOKANA(TM) Demonstrate Novel Type 2 Diabetes Medicine Also Provided Greater Secondary Endpoint Reductions in Weight and Systolic Blood Pressure CHICAGO, June 23, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced results from a new 52-week Phase 3 clinical study, showing 300 milligrams (mg) of INVOKANA(TM) (canagliflozin) provided greater improvements in blood glucose control compared to a commonly prescribed therapy,...

2013-06-22 16:20:16

Data Presentation Demonstrates Value of Test in Stratifying a Patient's Risk of Developing Type 2 Diabetes RALEIGH, N.C., June 22, 2013 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the presentation of data from a clinical study at the 73(rd) Scientific Sessions of the...